)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Korro Bio (KRRO) investor relations material
Korro Bio Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Clinical-stage biopharma focused on RNA editing for rare and prevalent diseases, with a pipeline including KRRO-110 (AATD) and KRRO-121 (UCD/HE).
KRRO-110 produced functional protein in AATD patients but did not reach projected levels after a single administration; pivoting to GalNAc delivery for AATD with a candidate nomination expected in H1 2026.
KRRO-121 nominated as a new GalNAc-conjugated candidate for hyperammonemia, targeting UCD and HE, with first-in-human trial filing anticipated in H2 2026.
Strategic restructurings in May and November 2025 reduced workforce by 19% and 34% to extend cash runway into H2 2027.
Novo Nordisk collaboration paused for 12 months as of November 2025.
Chief Medical Officer Dr. Kemi Olugemo resigned effective November 12, 2025.
Financial highlights
Net loss of $67.2M for the nine months ended September 30, 2025, compared to $62.4M in the prior year period.
Net loss for Q3 2025 was $18.1M, compared to $21.0M in Q3 2024.
Collaboration revenue of $5.1M recognized in 2025 from Novo Nordisk agreement; $1.1M in Q3 2025, none in 2024.
R&D expenses increased to $54.6M (from $46.7M) for the nine months ended September 30, 2025; Q3 2025 R&D expenses decreased to $13.8M from $16.0M in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $102.5M as of September 30, 2025, down from $163.1M at year-end 2024.
Outlook and guidance
Cash runway expected to fund operations into the second half of 2027, based on current assumptions and restructuring.
No material collaboration revenue expected during the 12-month pause with Novo Nordisk.
Plans to nominate a GalNAc-conjugated AATD candidate in H1 2026 and submit first-in-human trial for KRRO-121 in H2 2026.
Advancing additional GalNAc-conjugated programs for liver-targeted indications.
KRRO-110 PK differences: What specific insights?
KRRO-121: How does its mechanism expand OPERA?
Novo Nordisk collaboration pause: What's the impact?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Korro Bio earnings date
Q4 202518 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Korro Bio Inc. is a biopharmaceutical company engaged in the field of RNA editing to develop new genetic medicines. The company's innovative approach, leveraging the Oligonucleotide Promoted Editing of RNA (OPERA) platform, aims to harness natural processes for making transient, reversible changes to genetic instructions. This technology seeks to offer potential treatments for patients with rare and highly prevalent diseases by overcoming the complexities of earlier gene-editing methods. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage